Quitting smoking is one of the hardest behavioral changes a person can make, and weight gain after quitting is a well-documented reason many people either avoid trying or return to smoking after a short break. Now, a recruiting multi-site clinical trial is asking whether a peptide that simultaneously targets two gut-hormone receptors might address both problems at once.
The trial, registered under identifier NCT07602699, is enrolling 300 adults who smoke and who have a body mass index of 25 or higher. Participants will be randomly assigned to receive either tirzepatide or a placebo for 16 weeks, while everyone in both groups also uses nicotine patches. The research teams are based at the University of Southern California, Yale University, the University of Chicago, and the University of Colorado Anschutz Medical Campus.
Tirzepatide is a synthetic peptide that activates receptors for two naturally occurring hormones, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both receptors are found in tissues involved in appetite regulation, blood sugar handling, and reward signaling. The trial is designed to generate rigorous data on whether activating those pathways influences smoking behavior, not just body weight.
The research question behind the trial
The trial record frames two primary questions. First, does tirzepatide improve smoking cessation rates compared with placebo when both groups receive nicotine patches? Second, does the peptide limit post-cessation weight gain, which is a common barrier that leads people to resume smoking?
These are separate but connected outcomes. The literature on GLP-1 receptor agonists has already produced early signals that this class of peptides may influence addictive behaviors, possibly because GLP-1 receptors are expressed in dopamine-rich areas of the brain that process reward. Tirzepatide adds GIP receptor activity on top of that, making it a more complex compound to study in the context of behavior. This trial is designed to produce controlled, placebo-compared data rather than rely on anecdotal or observational reports.
How the trial is structured
The design is a parallel-arm, dose-escalating, placebo-controlled study. Parallel-arm means participants are split into two groups that run simultaneously rather than crossing over between conditions. Dose-escalating means the tirzepatide group starts at a lower weekly dose and increases over time, following a standard titration schedule. The starting dose is 2.5 mg per week, and the protocol brings participants up to 10 mg per week by the end of the 16-week active treatment period.
After the 16 medication weeks, participants attend follow-up visits at week 17 and week 27. The week-27 visit extends the observation window to about three months after the active intervention ends, which allows researchers to assess whether any cessation effects persist once dosing stops.
Subcutaneous injection is the delivery route for both tirzepatide and the placebo. All participants receive nicotine patches throughout, so the design is testing tirzepatide as an add-on to an established nicotine replacement strategy rather than as a standalone approach.
Why overweight and obesity matter here
The trial specifically recruits people with a BMI of 25 kg per square meter or higher. That threshold covers the overweight and obese categories. This is not an arbitrary restriction. Post-cessation weight gain is especially pronounced in people who already carry extra weight, and fear of further weight gain is a documented predictor of relapse. By studying a population where weight concern is already a real factor, the researchers can ask whether tirzepatide addresses that barrier directly.
From a metabolic standpoint, people with higher BMI also tend to show measurable disruptions in the GIP and GLP-1 signaling pathways that tirzepatide targets. Whether those disruptions make the peptide more or less effective in this context is one of the things the trial data could help clarify.
The peptide mechanism in plain terms
GLP-1 is a hormone released by cells in the intestine after eating. It signals the pancreas to release insulin, slows gastric emptying so food moves through the stomach more gradually, and reaches receptors in the brain that are involved in satiety and, according to the literature, reward processing. GIP works through a related but distinct receptor and contributes to similar metabolic effects, including some that GLP-1 alone does not fully produce.
Tirzepatide is a single peptide molecule engineered to bind both receptors. In metabolic research, the dual-agonist design has been studied for its effects on blood glucose and body weight. The smoking cessation hypothesis extends from the observation that the brain reward circuit, which nicotine also targets, overlaps with the circuitry where GLP-1 receptors are active. If those receptors help modulate how rewarding nicotine feels, then activating them pharmacologically might reduce the pull of the habit. That remains a hypothesis the trial is designed to test.
What the trial can and cannot tell us
A randomized, placebo-controlled design with 300 participants across four sites is a meaningful sample for an early efficacy trial. The four-site structure also means results will not reflect the quirks of a single research population or clinical setting, which strengthens any signal the researchers detect.
That said, the trial has a defined scope. It is recruiting treatment-seeking people who smoke with overweight or obesity, so results will apply most directly to that group. People with lower BMI, people who are not actively trying to quit, or people without access to weekly clinic visits for 16 weeks are not represented in this design.
The trial is also studying tirzepatide on top of nicotine patches, not as a replacement for them. Any efficacy finding will reflect the combination, not tirzepatide alone. That is a reasonable clinical design, but it means the data will not cleanly answer what tirzepatide does independently of nicotine replacement.
Finally, the week-27 follow-up is helpful but relatively short for studying long-term cessation. Whether any benefit persists beyond that window would require a longer study.
Context in the broader peptide research landscape
Interest in GLP-1 and dual-receptor peptides has expanded well beyond metabolic disease. Published research and registered trials now cover alcohol use, opioid craving, and addictive behavior more broadly. The smoking cessation trial described here fits into that growing body of inquiry rather than standing alone.
For researchers and curious readers tracking where peptide science is heading, this trial is a useful marker. It represents a formal, controlled attempt to determine whether the mechanisms that make dual-receptor peptides interesting for weight and glucose research extend meaningfully into behavioral neuroscience. The trial is currently recruiting, and results are expected to contribute to the evidence base rather than settle the question definitively on their own.
